Clinical Trials Directory

Trials / Completed

CompletedNCT02843581

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Fuda Cancer Hospital, Guangzhou · Academic / Other
Sex
All
Age
30 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced esophageal cancer.

Detailed description

By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for advanced esophageal cancer. The safety will be evaluated by statistics of adverse reactions.The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Conditions

Interventions

TypeNameDescription
DEVICECryosurgeryArgon-helium cryosurgical system
BIOLOGICALNK immunotherapyNutral killer cell immunotherapy for more than 6 times

Timeline

Start date
2016-07-01
Primary completion
2017-07-01
Completion
2019-07-01
First posted
2016-07-26
Last updated
2019-09-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02843581. Inclusion in this directory is not an endorsement.

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer (NCT02843581) · Clinical Trials Directory